▶ KLOW BLEND · SUBTOPIC · SAFETY PROFILE

KLOW BLEND Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of KLOW BLEND.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of KLOW BLEND. Severity, frequency, and attribution depend on the source publication.

Inherits side-effect profiles of all four component peptides

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for KLOW BLEND.

Per-component interactions apply

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for KLOW BLEND in the published record:

Per-component contraindications apply (most restrictive: Wilson's disease for the GHK-Cu component, pregnancy for all)

FDA REGULATORY STATUS

Not FDA-approved as a finished drug under this combinatorial label. Per-component status varies.

WADA REGULATORY STATUS

Per-component WADA status varies. GHK-Cu, kisspeptin-10, and oxytocin are not currently listed. BPC-157 (if substituted in the formulation) is prohibited under S0.

SAFETY Q+A FROM LITERATURE

▶ Is KLOW FDA-approved?

No. None of the four KLOW components is FDA-approved as a finished drug under this combinatorial label. The blend is supplied as a research-grade chemical reference compound for laboratory use only.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

Kotani M, Detheux M, Vandenbogaerde A, et al.. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of GPR54. J Biol Chem 2001. link
Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001. link

◀ KLOW BLEND OVERVIEW MECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-19